Key statistics
On Friday, Esperion Therapeutics Inc (0ET:FRA) closed at 1.96, -34.40% below its 52-week high of 2.99, set on Apr 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.75 |
---|---|
High | 1.96 |
Low | 1.75 |
Bid | 2.08 |
Offer | 2.18 |
Previous close | 1.88 |
Average volume | 1.23k |
---|---|
Shares outstanding | 196.22m |
Free float | 194.43m |
P/E (TTM) | -- |
Market cap | 447.39m USD |
EPS (TTM) | -0.6585 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 14:45 GMT.
More ▼
Announcements
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
- Esperion to Participate in Upcoming Jefferies London Healthcare Conference
- Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
- Esperion to Report Third Quarter 2024 Financial Results on November 7
- Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
- Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
- Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
- Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
More ▼